Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ibrigampar - Coherus BioSciences

Next Previous
X
Search
Drug Profile

Ibrigampar - Coherus BioSciences

Alternative Names: AMG-131; CHS-131; INT-131; INT131 besylate; T-0903131; T-131

Latest Information Update: 30 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tularik
  • Developer Coherus BioSciences; InteKrin Therapeutics
  • Class Anti-inflammatories; Antihypercalcaemics; Antihyperglycaemics; Chlorobenzenes; Hepatoprotectants; Insulin sensitisers; Neuroprotectants; Quinolines; Small molecules; Sulfonamides
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists; Peroxisome proliferator-activated receptor gamma modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Multiple sclerosis; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus

Most Recent Events

  • 31 Dec 2021 Discontinued - Phase-I/II for Non-alcoholic steatohepatitis in USA (PO), prior to December 2021
  • 31 Dec 2021 Discontinued - Phase-II for Multiple sclerosis (Treatment-naive) in Russia (PO), prior to December 2021
  • 31 Dec 2021 Discontinued - Phase-II for Type 2 diabetes mellitus in USA and Mexico (PO), prior to December 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top